Article Text

GW24-e2357 Role of serum activity of matrix metalloproteinase-9 in restenosis rate after implantation of drug-eluting stents
  1. Dong Shi Mei,
  2. Yu-yang Liu,
  3. Hong-ya Han,
  4. Yu-jie Zhou
  1. Department of Cardiology, Beijing Anzhen Hospital of Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases


Objectives To test whether serum level of matrix metalloproteinase (MMP)-9 is associated with the development of in-stent restenosis (ISR) in patients treated with drug-eluting stents (DES).

Methods 120 patients who were treated with DES were enrolled into our study. Blood samples for measurement of MMP-9 antigen and activity were taken directly before and 48h after percutaneous coronary intervention (PCI). Restenosis was evaluated at 9–12 months by coronary angiography.

Results During the follow-up period, 1 patients (0.8%) died of cardiovascular causes, and 7 patients (5.8%) developed angiographic ISR. Patients with ISR showed significantly higher serum activity of MMP-9 at baseline (p < 0.01) and after the procedure (p < 0.01). The PCI increased serum activity of MMP-9 (p = 0.008) only in patients with ISR.

Conclusions Elevated serum activity of MMP-9 is associated with dramatically increased restenosis rates after PCI with implantation of DES. Assessment of MMP-9 level might be useful for identification of patients who are at high risk for ISR despite implantation of DES.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.